Literature DB >> 26332552

Treating Myeloproliferation--On Target or Off?

Mary Armanios1, Carol W Greider.   

Abstract

Mesh：

Substances：

Year:  2015        PMID： 26332552     DOI： 10.1056/NEJMe1508740

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  13 in total

1.  Imetelstat, a telomerase inhibitor, differentially affects normal and malignant megakaryopoiesis.

Authors:  G Mosoyan; T Kraus; F Ye; K Eng; J D Crispino; R Hoffman; C Iancu-Rubin
Journal:  Leukemia       Date:  2017-03-08       Impact factor: 11.528

Review 2.  Biological and clinical implications of telomere dysfunction in myeloid malignancies.

Authors:  Ashwin Kishtagari; Justin Watts
Journal:  Ther Adv Hematol       Date:  2017-10-06

Review 3.  Social Media and Myeloproliferative Neoplasms (MPN)--Focus on Twitter and the Development of a Disease-specific Community: #MPNSM.

Authors:  Naveen Pemmaraju; Vikas Gupta; Ruben Mesa; Michael A Thompson
Journal:  Curr Hematol Malig Rep       Date:  2015-12       Impact factor: 3.952

4.  Imetelstat, a telomerase inhibitor, is capable of depleting myelofibrosis stem and progenitor cells.

Authors:  Xiaoli Wang; Cing Siang Hu; Bruce Petersen; Jiajing Qiu; Fei Ye; Jane Houldsworth; Kevin Eng; Fei Huang; Ronald Hoffman
Journal:  Blood Adv       Date:  2018-09-25

Review 5.  Telomerase as a therapeutic target in glioblastoma.

Authors:  Elisa Aquilanti; Lauren Kageler; Patrick Y Wen; Matthew Meyerson
Journal:  Neuro Oncol       Date:  2021-12-01       Impact factor: 13.029

Review 6.  Telomere and Telomerase Therapeutics in Cancer.

Authors:  Yucheng Xu; Amir Goldkorn
Journal:  Genes (Basel)       Date:  2016-05-26       Impact factor: 4.096

Review 7.  Telomeres and Telomerase in Hematopoietic Dysfunction: Prognostic Implications and Pharmacological Interventions.

Authors:  Theresa Vasko; Andrea Kaifie; Matthias B Stope; Thomas Kraus; Patrick Ziegler
Journal:  Int J Mol Sci       Date:  2017-10-28       Impact factor: 5.923

8.  How DNA damage and non-canonical nucleotides alter the telomerase catalytic cycle.

Authors:  Samantha L Sanford; Griffin A Welfer; Bret D Freudenthal; Patricia L Opresko
Journal:  DNA Repair (Amst)       Date:  2021-07-31

9.  BRD4 inhibitors block telomere elongation.

Authors:  Steven Wang; Alexandra M Pike; Stella S Lee; Margaret A Strong; Carla J Connelly; Carol W Greider
Journal:  Nucleic Acids Res       Date:  2017-08-21       Impact factor: 16.971

Review 10.  Targeting telomerase for cancer therapy.

Authors:  Adam N Guterres; Jessie Villanueva
Journal:  Oncogene       Date:  2020-07-30       Impact factor: 9.867
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.